Liminatus Pharma amends InnocsAI merger terms, targets July 2 close
PUBT · 2d ago
Share
Listen to the news
- Liminatus amended and restated its merger agreement with InnocsAI, restructuring terms to allow closing before stockholder approval.
- Closing is expected on July 2, 2026, subject to customary closing conditions.
- InnocsAI holders to receive Liminatus common stock and non-voting convertible preferred stock priced at USD 0.20 per share.
- Implied transaction value about USD 320 million; includes contingent value rights for 20% of future net proceeds from certain strategic transactions.
- Common stock portion capped at an estimated 19.99% of pre-closing shares; preferred converts only after stockholder approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606301630PRIMZONEFULLFEED9755007) on June 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved